Drug Trial Radar · NCT02711345
A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.
Last checked: Nov 19, 2026Latest source record: Sep 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
65
Actual
Start
Apr 15, 2016
Primary completion
Nov 21, 2018
Study completion Nov 21, 2018
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 17, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase I study of LTT462 in patients with advanced solid tumors that harbor MAPK pathway alterations.
Conditions
- Ovarian Neoplasms
- Non-Small-Cell Lung Carcinoma
- Melanoma
- Other Solid Tumors
Interventions
LTT462Drug
ERK Inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 2.8 years
- Percentage of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to 2.8 years
- Percentage of Participants With at Least One Dose ReductionTime frame: Up to 2.8 years
- Percentage of Participants With at Least One Dose InterruptionsTime frame: Up to 2.8 years
- Dose Intensity Received by ParticipantsTime frame: Up to 2.8 years
Locations
7 sites in 6 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
New York, New York
Novartis Investigative Site
Houston, Texas
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Chuo Ku, Tokyo, Japan
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Bellinzona, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.